Tag
Personal data from genetic tests has been used in drug development and research.
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Drug shortages are nothing new in U.S. hospitals.
The question is, who pays?
The European Union has some 20 "biosimilar" generics on the market; the US has one.
Drug makers are raising concerns Brexit could delay regulatory approval, slow down funding for basic research
Investors' demands for more profits left patients with the choice to pay up or die.
Some manufacturers are willing to tie drug price to performance.
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
